Pursuant to Second proviso to Regulation 30(6) and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.6 pts less than Nifty Microcap 250 and 1.2 pts more than its Other Financial Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The board of Biogen Pharmachem Industries Ltd met on 23rd March 2026 and approved several key items, the most significant being a bonus issue in the ratio of 1:6 (1 bonus share for every 6 shares held). This will lead to issuance of approximately 15.04 crore new equity shares of Re. 1 each, raising the paid-up capital from Rs. 90.26 crore to Rs. 105.30 crore. The bonus will be funded from the Securities Premium of Rs. 17 crore available as on 31st March 2025, with Rs. 15.04 crore being utilised. The board also increased the authorised share capital from Rs. 91 crore to Rs. 108 crore and altered the Capital Clause in the MOA. A new statutory auditor, M/s. Goenka Mehta & Associates, was appointed to fill a casual vacancy caused by the resignation of the previous auditor due to medical reasons. All key decisions, including the bonus issue, require shareholder approval through a postal ballot.
The 1:6 bonus issue rewards existing shareholders with additional shares, though it is a relatively modest ratio, so the price will adjust downward on the ex-date. Investors should watch for the record date announcement and the postal ballot outcome. The auditor change is routine and not material.